SLRX
Income statement / Annual
Last year (2023), Salarius Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Salarius Pharmaceuticals, Inc.'s net income was -$12,542.69.
See Salarius Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$1.84 M
|
$5.23 M
|
$3.47 M
|
$838,000.00
|
$1.28 M
|
$1.01 M
|
$0.00
|
| Cost of Revenue |
$10,051.00 |
$6,677.00 |
$19,183.00 |
$6,913.85 |
$4,018.95 |
$431,000.00 |
$507,000.00 |
$663,000.00 |
$49,881.00 |
| Gross Profit |
-$10,051.00 |
-$6,677.00 |
$1.82 M |
$5.23 M |
$3.46 M |
$407,000.00 |
$768,000.00 |
$348,000.00 |
-$49,881.00 |
| Gross Profit Ratio |
0 |
0 |
0.99 |
1 |
1 |
0.49 |
0.6 |
0.34 |
0 |
| Research and Development
Expenses |
$7,173.75
|
$15.84 M
|
$8.55 M
|
$6.91 M
|
$4.02 M
|
$11.91 M
|
$16.99 M
|
$20.38 M
|
$12.75 M
|
| General & Administrative
Expenses |
$5,721.20
|
$7.14 M
|
$6.10 M
|
$6.11 M
|
$7.71 M
|
$2.35 M
|
$1.37 M
|
$797,485.00
|
$0.00
|
| Selling & Marketing
Expenses |
$5.71 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.22 M
|
$17.14 M
|
$19.06 M
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5,721.20
|
$7.14 M
|
$6.10 M
|
$6.11 M
|
$7.71 M
|
$10.57 M
|
$18.50 M
|
$19.86 M
|
$16.46 M
|
| Other Expenses |
$0.00 |
$8.87 M |
-$4.00 |
-$178,587.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$12,894.00 |
$22.98 M |
$14.65 M |
$12.84 M |
$11.73 M |
$22.48 M |
$35.49 M |
$40.23 M |
$29.21 M |
| Cost And Expenses |
$12,894.00 |
$22.98 M |
$14.65 M |
$12.84 M |
$11.73 M |
$22.91 M |
$36.00 M |
$40.90 M |
$29.21 M |
| Interest Income |
$352,251.00 |
$218,730.00 |
$0.00 |
$0.00 |
$15,647.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$233,184.00 |
$0.00 |
-$3,047.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$10.05
|
$6,677.00
|
$19,183.00
|
$18,058.00
|
$16,934.00
|
$16,950.00
|
$324,548.00
|
$277,231.00
|
$49,881.00
|
| EBITDA |
-$12,884.89
|
-$14.12 M
|
-$12.86 M
|
-$7.85 M
|
-$9.45 M
|
-$22.07 M
|
-$34.73 M
|
-$39.89 M
|
-$29.21 M
|
| EBITDA Ratio |
0 |
0 |
-6.99 |
-1.5 |
-2.73 |
-26.34 |
-27.24 |
-39.45 |
0 |
| Operating Income Ratio
|
0
|
0
|
-6.96
|
-1.49
|
-2.76
|
-26.34
|
-27.24
|
-39.45
|
0
|
| Total Other
Income/Expenses Net |
$352.25
|
$233,184.00
|
$44,697.00
|
$434,091.00
|
$2.64 M
|
$152,006.00
|
$291,964.00
|
$393,109.00
|
$72,028.00
|
| Income Before Tax |
-$12,542.69 |
-$31.61 M |
-$12.77 M |
-$7.35 M |
-$6.94 M |
-$21.92 M |
-$34.43 M |
-$39.49 M |
-$29.14 M |
| Income Before Tax Ratio
|
0
|
0
|
-6.94
|
-1.4
|
-2
|
-26.16
|
-27.01
|
-39.06
|
0
|
| Income Tax Expense |
-$1.00 |
-$233,184.00 |
-$63,876.00 |
-$255,504.00 |
-$1.33 M |
$152,006.00 |
-$324,584.00 |
-$277,122.00 |
-$49,853.00 |
| Net Income |
-$12,542.69 |
-$31.37 M |
-$12.70 M |
-$7.10 M |
-$5.61 M |
-$21.92 M |
-$34.43 M |
-$39.49 M |
-$29.14 M |
| Net Income Ratio |
0 |
0 |
-6.9 |
-1.36 |
-1.62 |
-26.16 |
-27.01 |
-39.06 |
0 |
| EPS |
-30.74 |
-14.77 |
-7.68 |
-11.39 |
-42.9 |
-760.47 |
-1246.84 |
-1520.48 |
-1297.92 |
| EPS Diluted |
-30.74 |
-14.77 |
-7.68 |
-11.39 |
-42.9 |
-760.47 |
-1246.84 |
-1520.48 |
-1297.92 |
| Weighted Average Shares
Out |
$408.00
|
$2.12 M
|
$1.65 M
|
$623,144.00
|
$130,745.00
|
$28,827.00
|
$27,617.00
|
$25,974.00
|
$22,452.00
|
| Weighted Average Shares
Out Diluted |
$408.08
|
$2.12 M
|
$1.65 M
|
$623,144.00
|
$130,745.00
|
$28,827.00
|
$27,617.00
|
$25,974.00
|
$22,452.00
|
| Link |
|
|
|
|
|
|
|
|
|
